Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Halpin

Showing results (161-170 of 197) with videos related to

Pageof 20
Sort By:
International Journal of Chronic Obstructive Pulmonary Disease|August 2, 2022
Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT TrialAndrea Gabrio, Necdet B Gunsoy, Gianluca Baio, et al.
ERJ Open Research|March 15, 2021
Prognostic value of clinically important deterioration in COPD: IMPACT trial analysisMeiLan K Han, Gerard J Criner, Mark T Dransfield, et al.
The European Respiratory Journal|September 7, 2019
Misinterpretation of time-to-first event curves can lead to inappropriate treatmentBenjamin Hartley, Gerard J Criner, Mark T Dransfield, et al.
Advances in Therapy|July 11, 2020
Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT StudyMaggie Tabberer, C Elaine Jones, Sally Kilbride, et al.
Advances in Therapy|January 21, 2022
Correction to: Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT StudyMaggie Tabberer, C Elaine Jones, Sally Kilbride, et al.
Respiratory Research|June 7, 2020
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trialNicola C Day, Subramanya Kumar, Gerard Criner, et al.
Annals of the American Thoracic Society|October 27, 2020
Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACTMark T Dransfield, Courtney Crim, Gerard J Criner, et al.
Pulmonary Therapy|November 17, 2020
Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT TrialDavid M G Halpin, Gerard J Criner, Mark T Dransfield, et al.
Pragmatic and Observational Research|June 3, 2021
Maximizing Adherence and Gaining New Information For Your Chronic Obstructive Pulmonary Disease (MAGNIFY COPD): Study Protocol for the Pragmatic, Cluster Randomized Trial Evaluating the Impact of Dual Bronchodilator with Add-On Sensor and Electronic Monitoring on Clinical OutcomesDavid Price, Rupert Jones, Pascal Pfister, et al.
Chest|October 8, 2020
Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment TrialNicola A Hanania, David M Mannino, Gerard J Criner, et al.
Pageof 20

Showing results (161-170 of 197) with videos related to

Sort By:
Pageof 20
International Journal of Chronic Obstructive Pulmonary Disease|August 2, 2022
Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT TrialAndrea Gabrio, Necdet B Gunsoy, Gianluca Baio, et al.
ERJ Open Research|March 15, 2021
Prognostic value of clinically important deterioration in COPD: IMPACT trial analysisMeiLan K Han, Gerard J Criner, Mark T Dransfield, et al.
The European Respiratory Journal|September 7, 2019
Misinterpretation of time-to-first event curves can lead to inappropriate treatmentBenjamin Hartley, Gerard J Criner, Mark T Dransfield, et al.
Advances in Therapy|July 11, 2020
Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT StudyMaggie Tabberer, C Elaine Jones, Sally Kilbride, et al.
Advances in Therapy|January 21, 2022
Correction to: Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT StudyMaggie Tabberer, C Elaine Jones, Sally Kilbride, et al.
Respiratory Research|June 7, 2020
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trialNicola C Day, Subramanya Kumar, Gerard Criner, et al.
Annals of the American Thoracic Society|October 27, 2020
Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACTMark T Dransfield, Courtney Crim, Gerard J Criner, et al.
Pulmonary Therapy|November 17, 2020
Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT TrialDavid M G Halpin, Gerard J Criner, Mark T Dransfield, et al.
Pragmatic and Observational Research|June 3, 2021
Maximizing Adherence and Gaining New Information For Your Chronic Obstructive Pulmonary Disease (MAGNIFY COPD): Study Protocol for the Pragmatic, Cluster Randomized Trial Evaluating the Impact of Dual Bronchodilator with Add-On Sensor and Electronic Monitoring on Clinical OutcomesDavid Price, Rupert Jones, Pascal Pfister, et al.
Chest|October 8, 2020
Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment TrialNicola A Hanania, David M Mannino, Gerard J Criner, et al.
Pageof 20